InvestorsHub Logo
Followers 47
Posts 3929
Boards Moderated 0
Alias Born 03/04/2012

Re: farrell90 post# 380632

Friday, 10/29/2021 9:15:39 PM

Friday, October 29, 2021 9:15:39 PM

Post# of 402879
This is a post every new person should read. It explains this recent article in everyday language.

New Dr. Degrado article published October 21, 2021: Spiers Memorial Lecture: Analysis and de novo design of membrane-interactive peptides

https://pubs.rsc.org/en/content/articlelanding/2021/FD/D1FD00061F


The article confirms Dr Degrado, IPIX science advisor, is acknowledged by his peers as a leading researcher in the field of proteins, peptides
and defensins as well as defensin based pharmaceuticals.

Brilacidin is based structurally on a defensin peptide, Magainin. Attempts to make Magainin a therapeutic failed to to the structural weakness in its peptide core.

Dr Degrado and his team used biochemical and supercomputer enhancement to produce a new pharmacologically stable compound with superior antibiotic, anti-inflammatory and now antiviral capabilities, Brilacidin.

Having Dr DeGrado give a portion of a named lecture in his field is an honor .

Having Dr Degrado as IPIX's scientific advisor gives IPIX and Brilacidin scientific and academic credibility that is priceless.

Brilacidin research is just beginning to open its multiple possible uses as a pharmacologic agent.


GLTA,Farrell


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News